GLUE
Monte Rosa Therapeutics, Inc.
There isn't enough reported data to score GLUE yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
GLUE Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
GLUE's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
GLUE PE Valuation
GLUE has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
GLUE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect GLUE's losses to grow, with revenue declining. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
GLUE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.40 | -489% |
| Q2 2026 | -$1.76 | -540% |
| Q1 2026 | -$1.48 | -1333% |
| Q4 2025 | -$0.46 | +$0.52 |
| Q3 2025 | $0.36 | +$2.18 |
| Q2 2025 | $0.40 | +$2.63 |
| Q1 2025 | $0.12 | +$2.63 |
| Q4 2024 | -$0.98 | +$1.65 |
GLUE has swung to a loss: it lost $1.40 per share over the past year, after a profit the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over GLUE on earnings quality, reporting a profit while its opponent remains loss making.
GLUE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $54.4M | +326% |
| Q2 2026 | $9M | -61% |
| Q1 2026 | $4.2M | -95% |
| Q4 2025 | $2.8M | -95% |
| Q3 2025 | $12.8M | +39% |
| Q2 2025 | $23.2M | +394% |
| Q1 2025 | $84.9M | +7882% |
GLUE's revenue is recovering but still below its 2025 peak: $54M last quarter, up 326% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3.6% | +255 points |
| Q2 2026 | -548% | -481 points |
| Q1 2026 | -1188% | -1240 points |
| Q4 2025 | -1788% | -1809 points |
| Q3 2025 | -258% | +30 points |
| Q2 2025 | -67% | +628 points |
| Q1 2025 | 52% | +3336 points |
| Q4 2024 | 21% | N/A |
GLUE's operating margin was −3.6% last quarter, up 255 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over GLUE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over GLUE on profitability, with a higher operating margin.
GLUE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$42.5M | -143% |
| Q2 2026 | -$48.8M | -$12.4M |
| Q1 2026 | -$39.2M | +$7.8M |
| Q4 2025 | -$43.8M | -134% |
| Q3 2025 | $99.8M | +$121.2M |
| Q2 2025 | -$36.4M | -$6.6M |
| Q1 2025 | -$47.1M | -$7.5M |
| Q4 2024 | $128.7M | +361% |
GLUE has burned cash in almost every quarter: −$174M over the past year, against $145M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over GLUE on cash generation, producing positive trailing cash flow while its opponent burns cash.
GLUE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7% | +7.1M shares |
| 1 year | +32% | +26.2M shares |
| 3 years | +118% | +58.8M shares |
| 5 years | +155% | +66.1M shares |
| Available history | +400% | +86.9M shares |
GLUE has 109M diluted shares, up 32% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | $178,000 |
| Q1 2020 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over GLUE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
GLUE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -11.2x | Net Cash |
| Q2 2025 | -2.8x | Net Cash |
| Q1 2025 | -10.4x | Net Cash |
GLUE has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
GLUE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.0 | Neutral |
| Stochastic | 6.7 | Oversold |
GLUE's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
GLUE PE vs Healthcare Sector
| Metric | GLUE | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
GLUE has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
GLUE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.5 | 11% below |
| 20 week MA | $14.7 | 37% below |
| 50 week MA | $17.0 | 45% below |
| 100 week MA | $11.8 | 21% below |
| 200 week MA | $8.82 | 5.6% above |
GLUE has fallen below most of its moving averages, though it's still 5.6% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over GLUE on trend strength, trading above more of its moving averages.
GLUE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $18.9 | $20.9 | +11% |
| 2022 | $20.9 | $7.94 | -62% |
| 2023 | $7.94 | $5.65 | -29% |
| 2024 | $5.65 | $7.06 | +25% |
| 2025 | $7.06 | $17.3 | +145% |
| 2026 YTD | $17.3 | $9.31 | -46% |
GLUE's yearly returns have swung widely, from +145% in 2025 to −62% in 2022. It's down 46% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over GLUE on returns for 2026, with the stronger performance.